Cargando…
The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application
OBJECTIVES: This study assessed the regenerative efficacy of basic fibroblast growth factor (FGF) in a rabbit model of chronic vocal fold scarring and then confirmed its utility and safety in a prospective trial of patients with this condition. METHODS: FGF was injected three times, at 1-week interv...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Otorhinolaryngology-Head and Neck Surgery
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678041/ https://www.ncbi.nlm.nih.gov/pubmed/27671715 http://dx.doi.org/10.21053/ceo.2016.00941 |
_version_ | 1783277355376050176 |
---|---|
author | Ban, Myung Jin Park, Jae Hong Kim, Jae Wook Park, Ki Nam Lee, Jae Yong Kim, Hee Kyung Lee, Seung Won |
author_facet | Ban, Myung Jin Park, Jae Hong Kim, Jae Wook Park, Ki Nam Lee, Jae Yong Kim, Hee Kyung Lee, Seung Won |
author_sort | Ban, Myung Jin |
collection | PubMed |
description | OBJECTIVES: This study assessed the regenerative efficacy of basic fibroblast growth factor (FGF) in a rabbit model of chronic vocal fold scarring and then confirmed its utility and safety in a prospective trial of patients with this condition. METHODS: FGF was injected three times, at 1-week intervals, into a chronic vocal fold scar created in a rabbit model. After 1 month, mRNA level of procollagen I, hyaluronic acid synthetase 2 (HAS 2), and matrix metalloproteinase 2 (MMP 2) were analyzed by real-time polymerase chain reaction. The relative densities of hyaluronic acid (HA) and collagen were examined 3 months post-injection. From April 2012 to September 2014, a prospective clinical trial was conducted at a tertiary hospital in Korea. FGF was injected into the mild vocal fold scar of 17 consecutive patients with a small glottic gap. The patients underwent perceptual, stroboscopic, acoustic aerodynamic test, and Voice Handicap Index (VHI) survey prior to and 3, 6, and 12 months after FGF injection. RESULTS: FGF injection of the vocal fold scar decreased the density of collagen and increased mRNA level of HAS 2 and MMP 2 expression significantly compared to the control group injected with phosphate buffered solution in a rabbit model (P<0.05). In the clinical trial, significant improvements in the majority of the subjective and objective voice parameters were registered 3 months after FGF injection and were maintained at 12 months. Complications associated with the FGF injections, such as granuloma, were not observed during the follow-up period. CONCLUSION: Based on the animal model and the prospective clinical trial, vocal fold injections of FGF in patients with mild chronic vocal fold scarring can significantly improve voice quality for as long as 1 year and without side effects. Our results recommend the use of FGF vocal fold injection as an alternative treatment modality for mild chronic vocal fold scarring. |
format | Online Article Text |
id | pubmed-5678041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Korean Society of Otorhinolaryngology-Head and Neck Surgery |
record_format | MEDLINE/PubMed |
spelling | pubmed-56780412017-12-01 The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application Ban, Myung Jin Park, Jae Hong Kim, Jae Wook Park, Ki Nam Lee, Jae Yong Kim, Hee Kyung Lee, Seung Won Clin Exp Otorhinolaryngol Original Article OBJECTIVES: This study assessed the regenerative efficacy of basic fibroblast growth factor (FGF) in a rabbit model of chronic vocal fold scarring and then confirmed its utility and safety in a prospective trial of patients with this condition. METHODS: FGF was injected three times, at 1-week intervals, into a chronic vocal fold scar created in a rabbit model. After 1 month, mRNA level of procollagen I, hyaluronic acid synthetase 2 (HAS 2), and matrix metalloproteinase 2 (MMP 2) were analyzed by real-time polymerase chain reaction. The relative densities of hyaluronic acid (HA) and collagen were examined 3 months post-injection. From April 2012 to September 2014, a prospective clinical trial was conducted at a tertiary hospital in Korea. FGF was injected into the mild vocal fold scar of 17 consecutive patients with a small glottic gap. The patients underwent perceptual, stroboscopic, acoustic aerodynamic test, and Voice Handicap Index (VHI) survey prior to and 3, 6, and 12 months after FGF injection. RESULTS: FGF injection of the vocal fold scar decreased the density of collagen and increased mRNA level of HAS 2 and MMP 2 expression significantly compared to the control group injected with phosphate buffered solution in a rabbit model (P<0.05). In the clinical trial, significant improvements in the majority of the subjective and objective voice parameters were registered 3 months after FGF injection and were maintained at 12 months. Complications associated with the FGF injections, such as granuloma, were not observed during the follow-up period. CONCLUSION: Based on the animal model and the prospective clinical trial, vocal fold injections of FGF in patients with mild chronic vocal fold scarring can significantly improve voice quality for as long as 1 year and without side effects. Our results recommend the use of FGF vocal fold injection as an alternative treatment modality for mild chronic vocal fold scarring. Korean Society of Otorhinolaryngology-Head and Neck Surgery 2017-12 2016-09-27 /pmc/articles/PMC5678041/ /pubmed/27671715 http://dx.doi.org/10.21053/ceo.2016.00941 Text en Copyright © 2017 by Korean Society of Otorhinolaryngology-Head and Neck Surgery This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Ban, Myung Jin Park, Jae Hong Kim, Jae Wook Park, Ki Nam Lee, Jae Yong Kim, Hee Kyung Lee, Seung Won The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application |
title | The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application |
title_full | The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application |
title_fullStr | The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application |
title_full_unstemmed | The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application |
title_short | The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application |
title_sort | efficacy of fibroblast growth factor for the treatment of chronic vocal fold scarring: from animal model to clinical application |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678041/ https://www.ncbi.nlm.nih.gov/pubmed/27671715 http://dx.doi.org/10.21053/ceo.2016.00941 |
work_keys_str_mv | AT banmyungjin theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT parkjaehong theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT kimjaewook theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT parkkinam theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT leejaeyong theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT kimheekyung theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT leeseungwon theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT banmyungjin efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT parkjaehong efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT kimjaewook efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT parkkinam efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT leejaeyong efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT kimheekyung efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication AT leeseungwon efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication |